7/27/2011 | CVIG | S&P ups Genzyme notes
|
6/21/2011 | CVIG | Moody's ups Genzyme notes
|
5/26/2011 | CVIG | Moody's: Genzyme unchanged
|
2/16/2011 | CVIG | Moody's may up Genzyme
|
2/10/2011 | CVIG | S&P places Genzyme on positive watch
|
12/31/2010 | CVIG | S&P affirms Genzyme
|
6/14/2010 | CVIG | S&P rates Genzyme notes A-
|
6/14/2010 | CVIG | Moody's rates Genzyme notes Baa2
|
12/4/2008 | CVIG | S&P upgrades Genzyme
|
11/7/2008 | CV | Market Commentary: GM, Ford weaker after reported losses, cash burn; Sprint Nextel extends gains; Wyeth firm
|
10/22/2008 | CV | Genzyme to redeem $690 million of 1.25% convertibles on Dec. 1
|
2/14/2007 | CV | Market Commentary: Genzyme, Transocean climb on results; Teva gains further on outlook; Archer Daniels Midland plans deal
|
7/12/2006 | CV | Market Commentary: Genzyme, AAR jump outright with earnings; Archstone-Smith slows; Health Management gains further
|
4/24/2006 | CV | Market Commentary: Bausch and Lomb, Schlumberger get analysts' thumbs up; Halliburton, Medtronic shrug off reports
|
3/20/2006 | CV | Market Commentary: Kerzner buyout hurts hedge investors; BioMarin plans new deal; Time Warner Telecom offer seen as cheap
|
11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
7/20/2005 | CV | Market Commentary: Amgen rises in mixed convertibles trading as earnings reports roil GM, Kodak, boost Wyeth
|
7/18/2005 | CV | Market Commentary: Convertibles market pauses ahead of earnings; Genzyme falls amid mixed biotechs, Lucent, financials ease
|
7/14/2005 | CV | Market Commentary: GM, Ford convertibles move up in active trade; AMD, Genzyme, airlines also gain, other sectors quiet
|
6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
6/7/2005 | CV | S&P ups Genzyme view to positive
|
3/14/2005 | CV | Market Commentary: JetBlue a laggard as airline paper up; Delta bankruptcy fears weigh; PDLI gains; Aquila up; Xoma off
|
7/15/2004 | CV | Market Commentary: Caesars eases back to levels before Harrah's deal; EDS off 1.75-2.25 points on cut to junk
|
5/20/2004 | CV | Genzyme calls 3% convertibles
|
3/11/2004 | CV | New Issue: Merrill prices $25 million 7% callable Strides exchangeable for Genzyme
|
3/3/2004 | CV | S&P: Genzyme unaffected
|
3/3/2004 | CV | Market Commentary: Disney little changed on concerns besides Eisner; PSS soars to 106; Toys up on hoped-for store sales
|
2/2/2004 | CV | Market Commentary: El Paso, other power issues lower; Delta deal emerges as airlines' descent continues
|
12/9/2003 | CV | Genzyme greenshoe exercised, raising convertibles to $690 million
|
12/5/2003 | CV | Market Commentary: CenterPoint drops 2 points on unlikely asset sale to Reliant; JetBlue dives 7.5 on warning
|
12/4/2003 | CV | New Issue: Genzyme $600 million convertibles yield 1.25%, up 47.5%
|
12/4/2003 | CV | S&P rates new Genzyme convertibles BBB
|
12/4/2003 | CV | Market Commentary: Genzyme reoffered at 99.25, trades up to 100.25; other new issues active, but flat
|
12/3/2003 | CV | Genzyme $600 million convertible talked at 1.0-1.25%, up 47.5-52.5%
|
12/3/2003 | CV | Market Commentary: Dominion, Genzyme emerge; Concord soars to 111, slides to 105.25; Fairmont hits 104.5
|
7/28/2003 | CV | S&P rates new Health Management convertible
|
5/2/2003 | CV | Moody's puts GM on review
|
1/14/2003 | CV | Market Commentary: Some expect credit spread rally to begin leveling off; Oneok mandatory guidance emerges
|
12/20/2002 | CV | Market Commentary: Market quietly closes ahead of holiday-shortened weeks
|
6/20/2002 | CV | Market Commentary: Convertibles marked lower still in thin summer trading pattern
|
4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
1/24/2002 | CV | Market Commentary: Awaiting Ford terms, convertibles flat as market watched Greenspan, Enron hearings
|
10/22/2001 | CV | Market Commentary: Convertibles gain with stocks, new deals keep coming
|